search
Back to results

Exploring the Mechanisms of Indoxyl Sulfate Production by Oral Tryptophan Challenge Test

Primary Purpose

Healthy, Chronic Kidney Diseases

Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Doctor's Best L-Tryptophan
Sponsored by
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Healthy

Eligibility Criteria

20 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • (1) age older than 20 years
  • (2) no exposure to antibiotics or probiotics within the 3 months before entering the study.

Exclusion Criteria:

  • (1) recent gastrointestinal discomfort (such as nausea, vomiting, abdominal pain, constipation, or diarrhea) or
  • (2) a history of chronic diseases including diabetes mellites, hypertension, CVD, CKD, liver disease, malignancy, and autoimmune disease.
  • (3) pregnancy or breast feeding
  • (4) currently use of antipsychotics, Hypnotics, Demerol, Dextromethorphan, tramadol, pentazocine

Sites / Locations

  • Taipei Tzu Chi Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Tryptophan loading

Arm Description

All participants are introduced to receive tryptophan loading test.

Outcomes

Primary Outcome Measures

Indoxyl sulfate
serum and urine indoxyl sulfate concentration measurement

Secondary Outcome Measures

Indole-3-acetic acid
serum and urine Indole-3-acetic acid concentration measurement

Full Information

First Posted
September 29, 2019
Last Updated
December 8, 2019
Sponsor
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT04117191
Brief Title
Exploring the Mechanisms of Indoxyl Sulfate Production by Oral Tryptophan Challenge Test
Official Title
Exploring the Mechanisms of Indoxyl Sulfate Production by Oral Tryptophan Challenge Test
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
October 1, 2019 (Actual)
Primary Completion Date
November 30, 2019 (Actual)
Study Completion Date
November 30, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Cardiovascular disease (CVD) is prevalent in patients with chronic kidney disease (CKD) and is associated with extremely poor prognosis. Traditional risk factors for the general population, such as diabetes mellitus, high blood pressure, and dyslipidemia, are more common in patients with CKD but cannot fully explain the increased risk of this population. New evidence suggests that the uremic milieu itself plays a critical role in the development and progression of CVD. The gut microbiota is markedly altered in CKD, with overgrowth of bacteria that produce uremic toxins. Indoxyl sulfate (IS) is among the most representative gut-derived uremic toxins and has been most frequently implicated as a contributor to the pathogenesis of CVD in CKD. IS is converted from indole, a gut bacteria metabolite of dietary tryptophan, by two hepatic enzymes, CYP2E1 and SULT1A1. The majority of studies have assessed IS toxicity in cultured cells and animal models. However, human data have been conflicting and the benefit of using orally administered adsorbents to reduce IS levels in unselected CKD patients was not supported by results from the recent randomized controlled trials. IS levels may fluctuate widely from time to time with dietary intakes. The investigators hypothesize that a postprandial IS concentration may more reflect its toxicity than a single time point (fasting or predialysis IS) concentration measured in clinical studies. Therefore, the investigators plan to establish an oral tryptophan challenge test (OTCT) by using an oral loading of 2 gm tryptophan to simulate the postprandial increase of plasma IS. The investigators will recruit 60 healthy volunteers to undergo OTCT. A pharmacokinetic study of IS after the OTCT will be performed in 20 of them to verify and simplify the design of OTCT protocol. The results of OTCT will be integrated with whole metagenome analysis of fecal microbiota and genetic polymorphism analysis of CYP2E1 and SULT1A1 to explore the mechanisms of IS production. In addition to the known genes in microbe produces indoles, other supporting bacteria or genes will be examined by using metagenomic shotgun sequencing data.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy, Chronic Kidney Diseases

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
All the participants would be introduced to receive 2g tryptophan loading for exploring serum and urine indoxyl sulfate concentration.
Masking
None (Open Label)
Allocation
N/A
Enrollment
42 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tryptophan loading
Arm Type
Experimental
Arm Description
All participants are introduced to receive tryptophan loading test.
Intervention Type
Dietary Supplement
Intervention Name(s)
Doctor's Best L-Tryptophan
Intervention Description
2g tryptophan loading once
Primary Outcome Measure Information:
Title
Indoxyl sulfate
Description
serum and urine indoxyl sulfate concentration measurement
Time Frame
the area under curve of serum and urine indoxyl sulfate within 72 hours
Secondary Outcome Measure Information:
Title
Indole-3-acetic acid
Description
serum and urine Indole-3-acetic acid concentration measurement
Time Frame
the area under curve of serum and urine Indole-3-acetic acid within 72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: (1) age older than 20 years (2) no exposure to antibiotics or probiotics within the 3 months before entering the study. Exclusion Criteria: (1) recent gastrointestinal discomfort (such as nausea, vomiting, abdominal pain, constipation, or diarrhea) or (2) a history of chronic diseases including diabetes mellites, hypertension, CVD, CKD, liver disease, malignancy, and autoimmune disease. (3) pregnancy or breast feeding (4) currently use of antipsychotics, Hypnotics, Demerol, Dextromethorphan, tramadol, pentazocine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ting-Yun Lin, MD.
Organizational Affiliation
Taichung Tzu Chi Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Taipei Tzu Chi Hospital
City
New Taipei City
ZIP/Postal Code
231
Country
Taiwan

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Exploring the Mechanisms of Indoxyl Sulfate Production by Oral Tryptophan Challenge Test

We'll reach out to this number within 24 hrs